Tesaglitazar

ATC code

• None

Legal status

• Development terminated

CAS Number

• 251565-85-2 ^Y

PubChem CID

• 208901

Tesaglitazar

Clinical data
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name (2S)-2-Ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl) ethoxy]phenyl]propanoic acid
CAS Number	251565-85-2 Y
PubChem CID	208901
ChemSpider	180999 N
UNII	6734037O3L
KEGG	D01274 Y
ChEMBL	ChEMBL521632 N
CompTox Dashboard (EPA)	DTXSID4048773
ECHA InfoCard	100.201.079
Chemical and physical data
Formula	C20H24O6S
Molar mass	392.47 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O
InChI InChI=1S/C20H24O6S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1 N Key:CXGTZJYQWSUFET-IBGZPJMESA-N N
NY (what is this?)  (verify)

Tesaglitazar (also known as AZ 242) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for the management of type 2 diabetes.^[1]

The drug had completed several phase III clinical trials,^[2] however in May, 2006 AstraZeneca announced that it had discontinued further development.^[3]

Cardiac toxicity of tesaglitazar is related to mitochondrial toxicity caused by decrease in PPARγ coactivator 1-α (PPARGC1A, PGC1α) and sirtuin 1 (SIRT1).^[4]